159 related articles for article (PubMed ID: 37066770)
21. Tubulin inhibitors: pharmacophore modeling, virtual screening and molecular docking.
Niu MM; Qin JY; Tian CP; Yan XF; Dong FG; Cheng ZQ; Fida G; Yang M; Chen HY; Gu YQ
Acta Pharmacol Sin; 2014 Jul; 35(7):967-79. PubMed ID: 24909516
[TBL] [Abstract][Full Text] [Related]
22. Prediction of Novel Anoctamin1 (ANO1) Inhibitors Using 3D-QSAR Pharmacophore Modeling and Molecular Docking.
Lee YH; Yi GS
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30336555
[TBL] [Abstract][Full Text] [Related]
23. In silico Exploration of a Novel ICMT Inhibitor with More Solubility than Cysmethynil against Membrane Localization of KRAS Mutant in Colorectal Cancer.
Mouhcine M; Kadil Y; Segmani I; Rahmoune I; Filali H
Curr Comput Aided Drug Des; 2024 Jun; ():. PubMed ID: 38835128
[TBL] [Abstract][Full Text] [Related]
24. Screening for the selective inhibitors of MMP-9 from natural products based on pharmacophore modeling and molecular docking in combination with bioassay experiment, hybrid QM/MM calculation, and MD simulation.
Hou J; Zou Q; Wang Y; Gao Q; Yao W; Yao Q; Zhang J
J Biomol Struct Dyn; 2019 Aug; 37(12):3135-3149. PubMed ID: 30079817
[TBL] [Abstract][Full Text] [Related]
25. Pharmacophore-based drug design for the identification of novel butyrylcholinesterase inhibitors against Alzheimer's disease.
Jiang Y; Gao H
Phytomedicine; 2019 Feb; 54():278-290. PubMed ID: 30668379
[TBL] [Abstract][Full Text] [Related]
26. Pharmacophore modelling, docking and molecular dynamic simulation studies in the discovery of potential human renin inhibitors.
Halimi M; Hajipasha A
J Mol Graph Model; 2022 Nov; 116():108272. PubMed ID: 35932508
[TBL] [Abstract][Full Text] [Related]
27. Discovery of potential inhibitors for stat3: ligand based 3D pharmacophore, virtual screening, molecular docking, dynamic studies and
Lakshmanan K; T K P; K Pai SR; Rajagopal K; Byran G
J Biomol Struct Dyn; 2022; 40(21):11320-11338. PubMed ID: 34463213
[TBL] [Abstract][Full Text] [Related]
28. Pharmacophore-Based Virtual Screening and In-Silico Explorations of Biomolecules (Curcumin Derivatives) of
Ejaz SA; Aziz M; Fawzy Ramadan M; Fayyaz A; Bilal MS
Molecules; 2023 May; 28(10):. PubMed ID: 37241785
[TBL] [Abstract][Full Text] [Related]
29.
Vaghefinezhad N; Farsani SF; Gharaghani S
Curr Drug Discov Technol; 2021; 18(1):139-157. PubMed ID: 31721705
[TBL] [Abstract][Full Text] [Related]
30. Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification.
Islam MA; Pillay TS
J Mol Graph Model; 2015 Mar; 56():20-30. PubMed ID: 25541527
[TBL] [Abstract][Full Text] [Related]
31. Investigation of novel ligand targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery: complete pharmacophore approach.
Shanmugam V; Muthukrishnan S
J Biomol Struct Dyn; 2023; 41(23):14524-14539. PubMed ID: 36841551
[TBL] [Abstract][Full Text] [Related]
32. Molecular insight into isoform specific inhibition of PI3K-α and PKC-η with dietary agents through an ensemble pharmacophore and docking studies.
Bhaskar BV; Rammohan A; Babu TM; Zheng GY; Chen W; Rajendra W; Zyryanov GV; Gu W
Sci Rep; 2021 Jun; 11(1):12150. PubMed ID: 34108504
[TBL] [Abstract][Full Text] [Related]
33. Development, evaluation and application of 3D QSAR Pharmacophore model in the discovery of potential human renin inhibitors.
John S; Thangapandian S; Arooj M; Hong JC; Kim KD; Lee KW
BMC Bioinformatics; 2011 Dec; 12 Suppl 14(Suppl 14):S4. PubMed ID: 22372967
[TBL] [Abstract][Full Text] [Related]
34. Identification of potential inhibitors for HCV NS5b of genotype 4a by combining dynamic simulation, protein-ligand interaction fingerprint, 3D pharmacophore, docking and 3D QSAR.
El-Hassab MAE; El-Bastawissy EE; El-Moselhy TF
J Biomol Struct Dyn; 2020 Sep; 38(15):4521-4535. PubMed ID: 31647392
[TBL] [Abstract][Full Text] [Related]
35. Pharmacophore-based virtual screening of ZINC database, molecular modeling and designing new derivatives as potential HDAC6 inhibitors.
Poonia P; Sharma M; Jha P; Chopra M
Mol Divers; 2023 Oct; 27(5):2053-2071. PubMed ID: 36214962
[TBL] [Abstract][Full Text] [Related]
36. Investigation of non-hydroxamate scaffolds against HDAC6 inhibition: A pharmacophore modeling, molecular docking, and molecular dynamics simulation approach.
Zeb A; Park C; Son M; Rampogu S; Alam SI; Park SJ; Lee KW
J Bioinform Comput Biol; 2018 Jun; 16(3):1840015. PubMed ID: 29945500
[TBL] [Abstract][Full Text] [Related]
37. Molecular dynamics simulation, 3D-pharmacophore and scaffold hopping analysis in the design of multi-target drugs to inhibit potential targets of COVID-19.
Fayyazi N; Mostashari-Rad T; Ghasemi JB; Ardakani MM; Kobarfard F
J Biomol Struct Dyn; 2022; 40(22):11787-11808. PubMed ID: 34405765
[TBL] [Abstract][Full Text] [Related]
38. Ligand based 3D-QSAR model, pharmacophore, molecular docking and ADME to identify potential fibroblast growth factor receptor 1 inhibitors.
Huang L; Wu X; Fu X; Wang H; Tang B; Xiao Y; Zhou C; Zhao Z; Wan Y; Chen H; Tang Z; Yao H; Shan Z; Bu T
J Biomol Struct Dyn; 2022 Oct; 40(16):7584-7597. PubMed ID: 33734039
[TBL] [Abstract][Full Text] [Related]
39. Pharmacophore modeling, virtual screening, molecular docking studies and density functional theory approaches to identify novel ketohexokinase (KHK) inhibitors.
Kavitha R; Karunagaran S; Chandrabose SS; Lee KW; Meganathan C
Biosystems; 2015 Dec; 138():39-52. PubMed ID: 26521124
[TBL] [Abstract][Full Text] [Related]
40. Identification of selective MMP-9 inhibitors through multiple e-pharmacophore, ligand-based pharmacophore, molecular docking, and density functional theory approaches.
Jana S; Singh SK
J Biomol Struct Dyn; 2019 Mar; 37(4):944-965. PubMed ID: 29475408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
